Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

SecurityDGLY / Digital Ally, Inc. (25382P208)
Chairman, CEO & PresidentRoss Stanton E
IndustryRadio and Television Broadcasting and Communications Equipment
Institutional Owners15
Institutional Shares331,445 - 4.65%
Common Shares Outstanding7,132,331 shares (as of 2018-03-31)
Institutional Value$ 940,000 USD

Institutional Stock Ownership and Shareholders()

DGLY / Digital Ally, Inc. Institutional Ownership

Digital Ally, Inc. (NASDAQ:DGLY) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 331,445 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Honkamp Krueger Financial Services Inc /adv, Geode Capital Management, Llc, Garner Asset Management Corp, Seacrest Wealth Management, Llc, Ladenburg Thalmann Financial Services Inc, UBS Group AG, and BlackRock Fund Advisors.
Digital Ally, Inc. (NASDAQ:DGLY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="DGLY / Digital Ally, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-07-19 13F-HR Garner Asset Management Corp 10,000 24
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 550 550 0.00 1 1 0.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 49,500 49,500 0.00 294 208 -29.25
2017-02-10 13F-HR BlackRock Fund Advisors 889 889 0.00 5 4 -20.00
2018-04-19 13F-HR VALLEY NATIONAL ADVISERS INC 42 42 0.00 0 0
2018-05-15 13F-HR UBS Group AG 5,236 1,000 -80.90 14 3 -78.57
2018-05-15 13F-HR HONKAMP KRUEGER FINANCIAL SERVICES INC /ADV 24,936 24,936 0.00 67 65 -2.99
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 22,523 22,523 0.00 60 58 -3.33
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 2 2 0.00 0 0
2018-05-09 13F-HR BlackRock Inc. 50,389 50,389 0.00 133 131 -1.50
2018-05-15 13F-HR VANGUARD GROUP INC 162,538 162,538 0.00 439 422 -3.87
2018-04-20 13F-HR Seacrest Wealth Management, Llc 4,550 12
2018-05-14 13F-HR Resources Investment Advisors, Inc. 362 362 0.00 1 1 0.00
2018-05-14 13F-HR MORGAN STANLEY 712 200 -71.91 2 1 -50.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 3,964 3,964 0.00 11 10 -9.09
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 10,387 0 -100.00 28 0 -100.00

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Axon: Long-Term Potential Remains Strong Despite 175% Surge

2018-05-23 seekingalpha
Axon, also known as Taser has skyrocketed by about 175% since I recommended the stock in a previous article. (3-0)

Digital Ally's (DGLY) CEO Stanton Ross on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the 2018 first quarter results conference call. [Operator Instructions]. (3-0)

10 Risky (But Rewarding) Small-Cap Stocks to Buy Now

2018-04-27 investorplace
The market was up 22% over the course of the past year, led by giants like, Inc. (NASDAQ:AMZN) and Facebook Inc (NASDAQ:FB), before the bottom finally fell out and investors’ fears for a correction materialized. (295-1)

Digital Ally, Inc.: In Turbulent Waters

2018-04-25 seekingalpha
Overall YoY revenue declined by $2 million; service revenue increased by 16% and product revenues dipped by 15%. (3-1)

Digital Ally's (DGLY) CEO Stan Ross on Q4 2017 Results - Earnings Call Transcript

2018-04-13 seekingalpha
Digital Ally, Inc. (NASDAQ:DGLY) Q4 2017 Results Earnings Conference Call April 13, 2018 11:15 AM ET (3-0)

CUSIP: 25382P208